26 March 2024
26 March 2024
The FDA granted accelerated approval for the drug back in November 2022, and granted priority review in December 2023.
The latest approval for Ultomiris is based on positive data from the Phase III CHAMPION-NMOSD trial.
The acquisition also includes an earnout based on meeting specific operating efficiency metrics this year.
Novo Nordisk will pay up to $1.1bn in upfront and milestone-based payments, with the acquisition expected to close in Q2 2024.
Esperion Therapeutics’ Nexletol and Nexlizet are now available for patients with cardiovascular risk in the US.
From Organon & Co to Denali Therapeutics, Pharmaceutical Technology lists the top ten emerging US pharmaceutical companies in 2023 based on their revenues.
Landos develops new oral therapies for autoimmune diseases.
An unnamed Chinese partner takes on AR1001 in an APAC Alzheimer’s market predicted to be worth $2.6bn by 2030.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
